To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Lifecore Biomedical Launches Corgel™ BioHydrogel Hyaluronan Based Research Hydrogel
Read time: Less than a minute
Lifecore Biomedical, LLC has announced the commercial launch of its proprietary Corgel™ BioHydrogel research kits. Corgel is a hyaluronan (hyaluronic acid) based biocompatible hydrogel. It was initially conceived and developed by scientists at Cleveland Clinic as a tissue bulking agent and drug delivery matrix. The tunability of the matrix and the biocompatibility also allows for the direct inclusion of cells or bioactive agents.
Lifecore procured an exclusive license agreement with Cleveland Clinic in 2007 and has been actively developing the technology by completing ISO 10993 Safety and Toxicity studies, as well as exploring modifications and variables to the technology.
Lifecore now looks forward to collaborative development for use in surgical and transcatheter applications in vascular surgery, cardiology, ophthalmology, orthopedics, aesthetics, ENT, drug delivery, tissue engineering and regenerative medicine and several other medical fields.
Lifecore procured an exclusive license agreement with Cleveland Clinic in 2007 and has been actively developing the technology by completing ISO 10993 Safety and Toxicity studies, as well as exploring modifications and variables to the technology.
Lifecore now looks forward to collaborative development for use in surgical and transcatheter applications in vascular surgery, cardiology, ophthalmology, orthopedics, aesthetics, ENT, drug delivery, tissue engineering and regenerative medicine and several other medical fields.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
